2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - 278-282
Technology and Procedures, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Study Population, Human, Adult
PAPER

263 Low-dose BCMA/CD 3 bispecific antibody (CM 336) induces rapid and universal deep hematologic responses in newly diagnosed systemic AL amyloidosis: Primary analysis of the prospective phase 2 AL-003 trial

Qi Wang, MD, Jieqiong Zhou, MD2, Jian Cui, MD, PhD3, qiling shi, MD4, Yuntong Liu5, yong yu, MD6, Lu-Gui Qiu, PhD7, Gang An, MD8
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, tianjin, China
2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, tianjin, China
3 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, tianjin, China
4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, tianjin, China
5 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, tianjin, China
6 Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, tianjin, China
7 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, tianjin, China
8 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, tianjin, China

Background

Systemic immunoglobulin light-chain (AL) amyloidosis arises from clonal plasma cells with cardiac involvement driving early mortality. Approximately 40% of patients still fail to reach a deep response, and early deaths remain a major unmet need, particularly in patients with advanced cardiac disease. BCMA/CD3 bispecific antibodies have shown high response rate in relapsed/refractory AL amyloidosis. We conducted the first prospective trial evaluating a BCMA/CD3 bispecific antibody (CM336) as frontline therapy in newly diagnosed AL amyloidosis.

 

Methods

AL-003 (NCT07151690) is a single-center, single-arm phase 2 trial of CM336, a humanized BCMA/CD3 bispecific antibody, in adults with previously untreated systemic AL amyloidosis. CM336 was administered subcutaneously in 28-day cycles for up to 12 cycles. During cycles 1 through 4, patients who had received at least two cycles of weekly therapy, had a partial response or better, and had a very good partial response or better by the end of cycle 4 were switched to 80 mg every 2 weeks during cycles 5 through 12. Primary endpoints were the ≥VGPR rate and safety. Bone marrow minimal residual disease (MRD) was measured by next-generation flow cytometry at 10?5 sensitivity. Adverse events were graded per CTCAE v 5.0 and CRS per the 2019 ASTCT criteria.

 

Results

As of the July 21, 2026 data cutoff, 21 patients had received at least one dose of CM336 and had undergone at least one hematologic response assessment; all were included in the efficacy and safety analyses. The median follow-up was 211 days (range, 92–323), and patients had received a median of 5 treatment cycles (range, 1–9). The median age was 65 years (IQR, 61-69), and the median baseline difference between involved and uninvolved free light chains (dFLC) was 319.8 mg/L (IQR, 118-445). Cardiac involvement was present in 18 patients (85.7%), renal involvement in 16 (76.2%), and involvement of at least two organs in 13 (61.9%). Mayo 2004 European-modification cardiac stage was I in 1 patient (4.8%), II in 16 (76.2%), IIIa in 2 (9.5%), and IIIb in 2 (9.5%); Palladini renal stage was I in 12 patients (57.1%), II in 8 (38.1%), and III in 1 (4.8%).

 

All 21 patients achieved a best hematologic response of VGPR or better, including CR in 15 (71.4%) and VGPR in 6 (28.6%) according to the 2021 ISA response criteria. Hematologic responses were rapid, with a median time to ≥PR of 10 days (IQR, 8–24) and a median time to CR of 49 days (IQR, 29–81). Among patients who underwent bone marrow MRD assessment, all achieved MRD negativity at a sensitivity of 10?5 (18/18, 100%).

 

With a median of 5 treatment cycles (range, 1–9), an overall organ response was achieved in 19 patients (90.5%), including organ CR in 7 (33.3%), VGPR in 3 (14.3%), and PR in 9 (42.9%). Among 18 patients with cardiac involvement, 14 were evaluable for cardiac response, of whom 10 (71.4%) achieved a cardiac response after a median of 38.5 days (range, 14–106). All 16 patients with renal involvement achieved a renal response (100%) after a median of 41.5 days (range, 14–178).

 

The most common treatment-emergent adverse events were lymphopenia (76.2%; grade 3–4, 61.9%) and hypogammaglobulinemia (71.4%; no grade 3–4 events). Grade ≥3 infections occurred in 13 patients (61.9%). CRS occurred in 3 patients (14.3%), all of grade 1–2 severity, with no grade ≥3 CRS and no immune effector cell–associated neurotoxicity syndrome (ICANS). Two patients with baseline cardiac involvement died during treatment, one from sudden cardiac death and one from acute heart failure complicated by atrial fibrillation; neither death was considered related to CM336.

 

Conclusion

In this first prospective frontline study of a BCMA/CD3 bispecific antibody in newly diagnosed AL amyloidosis, CM336 induced rapid, deep, and durable hematologic responses, accompanied by early organ responses in the majority of evaluable patients. Although grade ≥3 infections were frequent and two patients with baseline cardiac involvement died during treatment, CRS was infrequent, limited to grade 1–2, and no ICANS or treatment-related deaths were observed. These findings support further evaluation of BCMA/CD3 bispecific antibody therapy as a frontline treatment strategy for systemic AL amyloidosis.

Qi Wang, MD: No relevant conflicts of interest to declare.